ANDA 75453, held by Ivax Sub Teva Pharms. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75453 (Doxazosin Mesylate), held by Ivax Sub Teva Pharms, was first approved by FDA on Oct 18, 2000, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Nov 29, 2005 | Supplement 17Labeling | Approved | None posted |
| Dec 11, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Dec 11, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Dec 11, 2002 | Supplement 5Labeling | Approved | None posted |
| Dec 11, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Aug 28, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Aug 28, 2002 | Supplement 2Labeling | Approved | None posted |
| Jul 29, 2002 | Supplement 9Manufacturing | Approved | None posted |
| Oct 18, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters